Skip to main content

Table 3 Clinical impact of PET-CT

From: Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours

  

Major

Minor

No impact

GB

Initial staging

33 % (9/27)

7 % (2/27)

60 % (16/27)

Suspected recurrence

75 % (3/4)

0 % (0/4)

25 % (1/4)

Total

39 % (12/31)

6 % (2/31)

55 % (17/31)

CC intrahepatic

Initial staging

20 % (9/45)

11 % (5/45)

69 % (31/45)

Suspected recurrence

56 % (5/9)

44 % (4/9)

0 % (0/9)

Total

26 % (14/54)

17 % (9/54)

57 % (31/54)

CC extrahepatic

Initial staging

23 % (5/22)

9 % (2/22)

68 % (15/22)

Suspected recurrence

18 % (2/11)

64 % (7/11)

18 % (2/11)

Total

21 % (7/33)

27 % (9/33)

52 % (17/33)

CC All

Initial staging

21 % (14/67)

10 % (7/67)

69 % (46/67)

Suspected recurrence

35 % (7/20)

55 % (11/20)

10 % (2/20)

Total

24 % (21/87)

21 % (18/87)

55 % (48/87)

Total

 

28 % (33/118)

17 % (20/118)

55 % (65/118)

  1. GBC gallbladder carcinoma, CC cholangiocarcinoma